Page 18 - TD-1-2

Tumor Discovery

ORIGINAL RESEARCH ARTICLE
N6-methyladenosine-related long noncoding

RNA is a potential biomarker for predicting
pancreatic cancer prognosis

2
2
2
Yiyang Chen , Wanbang Zhou , Yiju Gong , and Xi Ou *
1,2
1 Anhui Medical University
2 Peking University Shenzhen Hospital Clinical School, Futian District, Shenzhen, Guangdong
Province, China

Abstract

Pancreatic cancer is a common malignant tumor of the digestive system, with
insidious onset, difficult early diagnosis, easy metastasis, and poor prognosis.
N6-methyladenosine (m6A) and long non-coding RNA (lncRNA) play important
roles in the prognostic value and immunotherapy response of pancreatic
adenocarcinoma (PAAD). Therefore, it is crucial to recognize m6A-related-lncRNAs in
PAAD patients. In this study, m6A-related lncRNAs were obtained by coexpression
analysis. Univariate, the Least Absolute Shrinkage, and Selection Operator (LASSO)
and multivariate Cox regression analyses were performed to construct m6A-related
lncRNA prognostic models. Kaplan–Meier analysis, principal component analysis,
feature-rich annotation, and nomogram were used to analyze the accuracy of risk
models. Potential drugs targeting this model are also discussed. A prognostic model
based on m6A-related lncRNAs was constructed, potential drugs targeting this m6A-
*Corresponding author: related lncRNAs feature were discovered, and the relationship with immunotherapy
Xi Ou
(bdszyyox@163.com) response was studied. Finally, a nomogram was established to predict survival in
PAAD patients. This m6A-based lncRNAs risk prognostic model may be promising
Citation: Chen Y, Zhou W, Gong Y, for clinical prediction of prognosis and immunotherapy response in PAAD patients.
et al., 2022, N6-methyladenosine-
related long noncoding RNA is a
potential biomarker for predicting
pancreatic cancer prognosis. Tumor Keywords: Bioinformatics; N6-methyladenosine; Long non-coding RNA; Pancreatic
Discov, 1(2): 165. adenocarcinoma
https://doi.org/10.36922/td.v1i2.165
Received: August 4, 2022
Accepted: September 23, 2022
Published Online: October 11, 2022 1. Introduction
Copyright: © 2022 Author(s).
This is an Open Access article Pancreatic adenocarcinoma (PAAD) is a common malignant tumor of the digestive
distributed under the terms of the system, with a high degree of malignancy and strong invasiveness [1,2] . Despite the
Creative Commons Attribution continuous development of multidisciplinary comprehensive treatment, pancreatic
License, permitting distribution,
and reproduction in any medium, cancer is often found at an advanced stage, and the prognosis of patients is still poor,
provided the original work is with a median survival time of 5 – 8 months. Its onset is insidious, its early diagnosis is
properly cited. difficult, and it is prone to metastasis. Despite the continuous new progress in the field
Publisher’s Note: AccScience of comprehensive treatment of pancreatic cancer, there is still little effect in improving
Publishing remains neutral with the prognosis of patients, and the 5-year survival rate is still <9% [3,4] . Therefore, it is very
regard to jurisdictional claims in important to find more effective clinical indicators for the diagnosis and treatment of
published maps and institutional
affiliations. pancreatic cancer patients.

Volume 1 Issue 2 (2022) 1 https://doi.org/10.36922/td.v1i2.165